Non-insulin agents for diabetes

Managing Diabetes

Volumn , Issue , 2012, Pages 61-89

  Sreemantula, Gayatri ^a   Shankarnarayan, Santosh ^b  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930169086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-908517-81-4_4     Document Type: Chapter

References (81)

1. Florez H. Sanchez A, Marks J. Type 2 diabetes. In: Diabetes in The Brain. London: Springer; 2009.
2. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-583.
3. DeFronzo R, Goodman A. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
4. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
5. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966.
6. Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Rockville, MD: Agency for Healthcare Research and Quality; 2007. www.effectivehealthcare.ahrq.gov/ehc/products/6/39/OralFullReport.pdf. Accessed September 5, 2012.
7. Brown JB, Connor C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501-506.
8. Salpeter S, Greyber E, Pasternak G, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(1):CD002967
9. National Insititute for Health and Clinical Excellence. Type 2 diabetes NICE clinical guideline 87; 2009. www.nice.org.uk/CG87. Accessed September 5, 2012.
10. Turner R. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
11. Schernthaner G, Grimaldi A, di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-542.
12. Wright A, Burden AC, Paisey RB, et al; for the UK. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
13. Patel A, MacMahon S, Chalmers J, et al; for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
14. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-1180.
15. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751-755.
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2010;304:411-418.
18. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-1195.
19. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD ): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135.
20. Dormandy JA, Charbonnel B, Eckland DJA, et al; for the PRO active investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (Prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet. 2005;366:1279-1289.
21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-1188.
22. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
23. Yki-Jarvinen H. Thiazolidinediones. N Eng J Med. 2004;351:1106-1118.
24. Nissen SE, Nissen SE, Wolski K. Effect of rosglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med. 2007; 2457-2471.
25. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetes patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
26. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32-39.
27. Scheen AT. Hepatotoxicity with thiazolidiones: is it a class effect? Drug Saf. 2001;12:873-888.
28. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogs for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD004654.
29. Bischoff H. Pharmacology of alpha-glucose inhibition. Eur J Clin Invest. 1994;24 (suppl 3):3-10.
30. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154-163.
31. Bolen S, Wilson L, Vassy J, Marinopolous S. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Rockville, MD: Agency for healthcare research and disability; 2007.
32. Taira M, Takasu N, Komiya I, Taira T, Tanaka H. Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy.Metabolism. 2000;4:440-443.
33. Hanefeld M. Alpha-glucose inhibitors. In: Goldstein BJ, Muller-Wieland D, eds. Type 2 Diabetes: Principles and Practice. Second edition. New York: Informa; 2008: 127.
34. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.
35. Lovshin, JA, Drucker, JD, et al. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009;5:262-269.
36. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(10):CD006423.
37. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
38. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics. 2006;28:1556-68.
39. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl. 2008;159:8-14.
40. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089-2112.
41. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427-430.
42. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780-789.
43. Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin. 2010;26:1647-1656.
44. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017-3022.
45. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13:55-64.
46. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-954.
47. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012; [Epub ahead of print].
48. Campbell RK, Cobble ME, Reid TS, Shomali ME. Safety tolerability and nonglycemia effects of incretin-based therapies. J Fam Pract. 2010;59(suppl 1): S20-S27.
49. White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620-626.
50. Marrs JC. Colesevelam for the management of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2009;5:187-194.
51. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
52. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12:384-392.
53. Welchol product information - cholesevelam hydrochloride. 2007. www.welchol.com/pi/htm. Accessed May 22, 2012.
54. Holt RIG, Barnett AH, Bailey CJ, et al. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12:1048-1057.
55. Scranton R, Cincotta A. Bromocriptine - unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269-279.
56. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia. 2006;49:2819-2823.
57. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-380.
58. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-2083.
59. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 2005;97:1679-1687.
60. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin's lymphoma: A meta-analysis of observational studies. Diabetes Care. 2008;31:2391-2397.
61. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056-2062.
62. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 2007;50:1365-1374.
63. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 2007;121:856-862.
64. Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer: insulin and IGF-1 signalling. Endocrine Practice. 2010;16:864-873.
65. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E: Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46:279-284.
66. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-77.
67. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODI AC-16. Diabetes Care. 2010;33:322.
68. Niraula S, Stambolic V, Dowling RJO, et al. Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res. 2010:70(Suppl 24):104S.
69. Hadad SM, Dewar JA, Elseedawy E et al. Gene Signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. J Clin Oncol. 2010;28(Suppl):560.
70. Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011;9:33.
71. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci. USA. 1998;95:8806-8811.
72. Clay CE, Namen AM, Astumi G, et al. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J. Investig. Med. 2001;49:413-420.
73. Dormandy JA, Charbonnel B, Eckland DJ, et al; for the PRO active investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PRO spective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
74. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PRO active. Drug Saf. 2009;32:187-202.
75. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369-1371.
76. Food and Drug Administration. FDA Drug Safety Communication. "Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer." FDA Website. www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed September 5, 2012.
77. Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS). "Use of medications containing pioglitazone (Actos®, Competact®) suspended." June 9th, 2011. AFSSAPS website.www.afssaps.fr/var/afssaps-site/storage/original/application/4e293bcd0814c025b94d46d7502a0958.pdf. Accessed September 5, 2012.
78. Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM). "Pioglitazon - Europäische Arzneimittelagentur empfiehlt neue Kontraindikationen und Warnhinweise fur pioglitazonhaltige Arzneimittel aufgrund eines leicht erhöhten Blasenkrebsrisikos [Pioglitazone: The European Medicines Agency recommends new contraindications and warnings for medicinal products containing pioglitazone due to a slightly increased risk of bladder cancer]." July 22, 2011. BfArM Website. www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/2011/pioglitazon.html?nn=1016416.Accessed September 5, 2012.
79. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-922.
80. European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. EM A website. www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/07/WC500109176.pdf. Accessed September 5, 2012.
81. European Medicines Agency. "European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer. Positive benefit-risk balance confirmed as second and third line treatment." EM A Website. October 21, 2011. www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/10/WC500116936.pdf. Accessed September 5, 2012.